Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.42 |
| ▸ | MOK | Q9UQ07 | 4/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5961510 | 0.92 | PTK6 (0.42) | LCKPTK6NR3C1MTOR | |
| SCHEMBL7137484 | 0.82 | SPR (0.43) | NR3C1SMN1; SMN2RAB9A | |
| SCHEMBL5961460 | 0.82 | NR3C1 (0.40) | LCKPTK6AURKBNR3C1CCNE1 | |
| SCHEMBL7074009 | 0.80 | NR3C1 (0.48) | NR3C1KMT2ARAB9A | |
| SCHEMBL7079006 | 0.79 | MEN1 (0.45) | NR3C1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5961577 | 0.78 | CCR2 (0.51) | NR3C1SMN1; SMN2 | |
| SCHEMBL7079264 | 0.77 | NR3C1 (0.40) | NR3C1 | |
| SCHEMBL7077952 | 0.77 | SPR (0.48) | NR3C1KMT2ARAB9A | |
| SCHEMBL7137004 | 0.76 | KMT2A (0.41) | MOKNR3C1MTORKMT2ACNR1 | |
| SCHEMBL5961443 | 0.75 | PTK6 (0.40) | PTK6NR3C1MTORRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | claimed |
| EP-1358188-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-05 | — | — | EP | claimed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | claimed |
| WO-2002060900-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-6992086-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | disclosed |
| EP-1358188-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-05 | — | — | EP | disclosed |
| WO-2002060900-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | LCK 460/4885PTK6 2002/4885AURKB 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.